Our most recent study has shown that continued use of trastuzumab in PTEN-deficient breast cancer cells induced the EMT, expands breast cancer stem cells (BCSCs)[10], and transform HER2+ to a trastuzumab-resistant triple negative phenotype [14]. Here, ERBB2 is linked to breast carcinoma.